



Stabilis



Tobramycin sulfate



Noms commerciaux

Bactob	Inde
Beltob	Inde
Bramicil	Italie
Brulamycin	Allemagne, Hongrie
Eltol	Inde
Fytobra	Inde
Gernebcin	Allemagne
Komitob	Inde
Nebcin	Afrique du sud, Arabie Saoudite, Australie, Egypte, Grande Bretagne, Grèce, Nouvelle Zélande
Nebcina	Danemark, Maroc, Norvège, Suède
Nebcine	France, Maroc
Nebicina	Italie
Obracin	Belgique, Luxembourg, Pays bas, Suisse
Tobel	Turquie
Tobra	Allemagne
Tobra-Gobens	Espagne
Tobraalex	Egypte
Tobracin	Egypte
Tobradistin	Espagne
Tobramicina	Espagne, Italie, Portugal
Tobramina	Brésil
Tobramycin	Allemagne, Australie, Canada, Etats Unis d'Amérique, Grande Bretagne, Irlande, Norvège
Tobramycine	Belgique, Luxembourg, Pays bas
Tobrasix	Autriche
Tobrazid	Allemagne
Tomycin	Finlande



Stabilité des solutions

PVC		1,2 mg/ml	-20°C		28			565
PVC		1,2 mg/ml	25°C		48			434
PVC		1,2 mg/ml	4°C		48			434

PVC		1 & 10 mg/ml	25°C		3			13
PVC		1 & 10 mg/ml	5°C		14			13
PVC		3,2 mg/ml	-20°C		30			575
EVA		0,95 mg/ml	23°C		7			1704
EVA		0,95 mg/ml	4°C		30			1704
		40 mg/ml	25°C		60			709
		40 mg/ml	4°C		60			709
		30 mg/ml	22°C-23°C		48			639
		0,5 & 5 mg/ml	25°C		24			604
		0,5 & 5 mg/ml	4°C		10			604



Stabilité en mélange

		3,2 mg/ml	25°C		Filgrastim : 40 µg/ml	4		104
		0,8 mg/ml	25°C		Ofloxacin : 2 mg/ml	48		889
PVC		1 mg/ml	25°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
PVC		0,2 & 0,8 mg/ml	25°C		Aztreonam : 10 & 20 mg/ml	48		19
PVC		0,2 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19
PVC		0,2 & 0,8 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		19
PVC		1 mg/ml	4°C		Ciprofloxacin lactate : 1,5 mg/ml	48		434
PVC		1,2 mg/ml	-20°C		Clindamycin phosphate : 9 mg/ml	28		565
PVC		1,2 mg/ml	-20°C		Clindamycin phosphate : 9 mg/ml	14		565
PVC		0,008 mg/ml	24°C		Ceftazidime : 0,125 mg/ml	16		2369
PVC		0,008 mg/ml	37°C		Ceftazidime : 0,125 mg/ml	8		2369
POF		0,80 mg/ml	23°C		Linezolid : 1,80 mg/ml	1		2353
POF		0,80 mg/ml	4°C		Linezolid : 1,80 mg/ml	7		2353



Compatibilités

	Tobramycin sulfate : 1.6 mg/ml Aciclovir sodium : 5 mg/ml	336













		Tobramycin sulfate : 5 mg/ml Allopurinol sodium : 3 mg/ml		307
		Tobramycin sulfate : 1 mg/ml Alprostadil : 15 µg/ml		3201
		Tobramycin sulfate : 5 mg/ml Amifostine : 10 mg/ml		3
		Tobramycin sulfate : 5 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Tobramycin sulfate : 0.8 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Tobramycin sulfate Amoxicillin sodium		3527
		Tobramycin sulfate Amoxicillin sodium / clavulanic acid		3545
		Tobramycin sulfate : 40 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Tobramycin sulfate : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Tobramycin sulfate : 5 mg/ml Amsacrine : 1 mg/ml		253
		Tobramycin sulfate : 5 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Tobramycin sulfate : 21 mg/ml Azithromycine : 2 mg/ml		1800
		Tobramycin sulfate : 5 mg/ml Aztreonam : 40 mg/ml		99
		Tobramycin sulfate : 0.2 & 0.8 mg/ml Aztreonam : 10 & 20 mg/ml		19
		Tobramycin sulfate : 5 mg/ml Bivalirudin : 5 mg/ml		1713
		Tobramycin sulfate : 40 mg/ml Caffeine : 10 mg/ml		3964
		Tobramycin sulfate : 5 mg/ml Calcium gluconate : 16 mg/ml		503
		Tobramycin sulfate : 1 mg/ml Calcium gluconate : 33 mg/ml		503
		Tobramycin sulfate Calcium gluconate		3644
		Tobramycin sulfate : 5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Tobramycin sulfate Cefamandole nafate : 2 >> 100 mg/ml		612
		Tobramycin sulfate Cefamandole nafate		3546
		Tobramycin sulfate : 6 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Tobramycin sulfate Cefepime dihydrochloride		3548
		Tobramycin sulfate : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Tobramycin sulfate Cefoperazone sodium		3544

		Tobramycin sulfate : 0.8 mg/ml Cefoperazone sodium : 10 & 40 mg/ml		1206
		Tobramycin sulfate Cefpirome sulfate		3677
		Tobramycin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Tobramycin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Tobramycin sulfate : 6 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Tobramycin sulfate : 6 mg/ml Ceftazidime : 125 mg/ml		2141
		Tobramycin sulfate : 0.008 mg/ml Ceftazidime : 0.125 mg/ml		2369
		Tobramycin sulfate Ceftazidime		3543
		Tobramycin sulfate Ceftazidime		3883
		Tobramycin sulfate Ceftobiprole medocaril sodium		4650
		Tobramycin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Tobramycin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Tobramycin sulfate : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Tobramycin sulfate Ceftriaxone disodium		3523
		Tobramycin sulfate Cefuroxime sodium		3687
		Tobramycin sulfate : 1 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Tobramycin sulfate : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Tobramycin sulfate : 1,6 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
		Tobramycin sulfate : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Tobramycin sulfate Cisplatin		3578
		Tobramycin sulfate Clindamycin phosphate		3526
		Tobramycin sulfate : 12 mg/ml Clindamycin phosphate : 90 mg/ml		639
		Tobramycin sulfate : 40 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Tobramycin sulfate : 10 mg/ml Defibrotide : 8 mg/ml		3728
		Tobramycin sulfate : 5 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Tobramycin sulfate : 2.4 & 40 mg/ml Diltiazem hydrochloride : 5 mg/ml		198

		Tobramycin sulfate Dimenhydrinate		2087
		Tobramycin sulfate : 5 mg/ml Docetaxel : 0.9 mg/ml		1754
		Tobramycin sulfate : 5 mg/ml Doripenem : 5 mg/ml		2262
		Tobramycin sulfate : 5 mg/ml Eravacycline : 0,6 mg/ml		4434
		Tobramycin sulfate : 5 mg/ml		1415
		Tobramycin sulfate : 5 mg/ml		301
		Tobramycin sulfate : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Tobramycin sulfate : 0.8 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Tobramycin sulfate : 0.8 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Tobramycin sulfate : 10 & 40 mg/ml		999
		Tobramycin sulfate : 10 mg/ml		316
		Tobramycin sulfate : 0,05 mg/ml		4445
		Tobramycin sulfate Erythromycin lactobionate		3674
		Tobramycin sulfate : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Tobramycin sulfate : 40 mg/ml		673
		Tobramycin sulfate : 5 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Tobramycin sulfate : 10 mg/ml Fentanyl citrate : 50 µg/ml		63
		Tobramycin sulfate : 1.6 mg/ml Filgrastim : 40 µg/ml		104
		Tobramycin sulfate : 5 mg/ml Filgrastim : 30 µg/ml		244
		Tobramycin sulfate Flucloxacillin sodium		3522
		Tobramycin sulfate : 8 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Tobramycin sulfate : 40 mg/ml Fluconazole : 2 mg/ml		496
		Tobramycin sulfate : 5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Tobramycin sulfate : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
		Tobramycin sulfate : 1,6 mg/ml Furosemide : 0,8 mg/ml		367
		Tobramycin sulfate : 0.8 mg/ml Heparin sodium : 50 UI/ml		317
		Tobramycin sulfate : 40 mg/ml	RL	4603
		Tobramycin sulfate : 5 mg/ml Fosfomicin : 30 mg/ml		4055

		Tobramycin sulfate : 8 mg/ml Furosemide : 1 mg/ml		1232
		Tobramycin sulfate : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Tobramycin sulfate : 5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Tobramycin sulfate Heparin sodium		3540
		Tobramycin sulfate : 5 mg/ml Hetastarch : 60 mg/ml		1721
		Tobramycin sulfate : 0.8 mg/ml Hetastarch : 60 mg/ml		472
		Tobramycin sulfate : 0.8 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Tobramycin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml		494
		Tobramycin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml		1745
		Tobramycin sulfate : 1.6 & 2 mg/ml Insulin : 0.2 UI/ml		129
		Tobramycin sulfate : 5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Tobramycin sulfate : 40 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Tobramycin sulfate : 0.8 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Tobramycin sulfate : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Tobramycin sulfate : 5 mg/ml Linezolid : 2 mg/ml		1925
		Tobramycin sulfate : 0,80 mg/ml Linezolid : 1,80 mg/ml		2353
		Tobramycin sulfate : 0.8 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Tobramycin sulfate : 5 mg/ml Melphalan : 0.1 mg/ml		169
		Tobramycin sulfate : 40 mg/ml Meropenem : 50 mg/ml		4319
		Tobramycin sulfate : 40 mg/ml Meropenem : 50 mg/ml		4389
		Tobramycin sulfate : 0.8 mg/ml Metronidazole : 5 mg/ml		1035
		Tobramycin sulfate Metronidazole		3594
		Tobramycin sulfate : 10 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Tobramycin sulfate : 1.6 >> 2.4 mg/ml Morphine sulfate : 1 mg/ml		406
		Tobramycin sulfate : 0.8 mg/ml Morphine sulfate : 1 mg/ml		405
		Tobramycin sulfate : 40 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408

		Tobramycin sulfate : 0.8 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Tobramycin sulfate : 0,8 mg/ml Ofloxacin : 2 mg/ml		889
		Tobramycin sulfate : 5 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Tobramycin sulfate Pantoprazole sodium		2090
		Tobramycin sulfate : 40 mg/ml Paracetamol : 10 mg/ml		4742
		Tobramycin sulfate : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Tobramycin sulfate : 0.8 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Tobramycin sulfate : 1.6 >> 2.4 mg/ml Pethidine hydrochloride : 10 mg/ml		406
		Tobramycin sulfate Piperacillin sodium		1168
		Tobramycin sulfate Piperacillin sodium / tazobactam		3586
		Tobramycin sulfate : 2 mg/ml Propofol		660
		Tobramycin sulfate : 5 mg/ml Propofol : 10 mg/ml		300
		Tobramycin sulfate : 5 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Tobramycin sulfate : 40 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Tobramycin sulfate : 5 mg/ml Sargramostim : 10 µg/ml		335
		Tobramycin sulfate : 2,4 mg/ml Sodium bicarbonate : 40 mg/ml		3122
		Tobramycin sulfate : 40 mg/ml Tacrolimus : 1000 µg/ml		479
		Tobramycin sulfate : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Tobramycin sulfate Teicoplanine		3656
		Tobramycin sulfate : 5 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Tobramycin sulfate Temocilline		2296
		Tobramycin sulfate : 6 mg/ml Temocilline : 83.33 mg/ml		2231
		Tobramycin sulfate : 5 mg/ml Teniposide : 0.1 mg/ml		905
		Tobramycin sulfate : 0.8 mg/ml Theophylline : 4 mg/ml		317
		Tobramycin sulfate : 40 mg/ml Thiopental sodium : 25 mg/ml		3767
		Tobramycin sulfate : 5 mg/ml Thiotepa : 1 mg/ml		249

		Tobramycin sulfate Ticarcillin / clavulanic acid		3587
		Tobramycin sulfate Tigecycline		3332
		Tobramycin sulfate : 6 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Tobramycin sulfate : 0.16 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Tobramycin sulfate : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Tobramycin sulfate : 2 mg/ml Zidovudine : 4 mg/ml		337



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
13	Revue	Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
19	Revue	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

104	Revue	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.

335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
367	Revue	Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Revue	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
434	Revue	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
472	Revue	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
494	Revue	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Hosp Pharm 1992 ; 49: 836,838.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	Revue	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.

503	Revue	Nahata MC, Durrell DE. Stability of tobramycin sulfate in admixtures with calcium gluconate. Am J Hosp Pharm 1985 ; 45: 1987-1988.
565	Revue	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.
575	Revue	Holmes CJ, Ausman RK, Kundsinn RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
612	Revue	Frable RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627.
639	Revue	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
673	Revue	Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN 1989 ; 13: 505-509.
709	Revue	Seitz DJ, Archambault JR, Brinck-Johnsen T. Stability of tobramycin sulfate in plastic syringes. Am J Hosp Pharm 1980 ; 37: 1614-1615.
889	Revue	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.

1168	Revue	Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H. Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin. Antimicrob Agents Chemother 1983 ; 23: 653-657.
1206	Revue	Frear RS. Cefoperazone-aminoglycoside incompatibility. Am J Hosp Pharm 1983 ; 40: 564.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1704	Revue	Xu QA, Trissel LA, Saenz A. Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags. Int J Pharm Compound 2002 ; 6: 152-154.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1745	Revue	Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Health-Syst Pharm 1992 ; 49: 836-838.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	Revue	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.



1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	Laboratoire	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2353	Revue	Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. Compatibility and stability of linezolid injection admixed with gentamicin sulfate and tobramycin sulfate. Int J Pharm Compound 2000 ; 4, 6: 476-479.
2369	Revue	Mason NA, Johnson CE, O'Brien MA. Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 1139 - 1142.

3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3122	Revue	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233-236.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3522	Laboratoire	Flucloxacillin - Summary of Product Characteristics. Actavis 2013
3523	Laboratoire	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3527	Laboratoire	Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3543	Laboratoire	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3544	Laboratoire	Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006
3545	Laboratoire	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3546	Laboratoire	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011


3586	Laboratoire	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Laboratoire	Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3656	Laboratoire	Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3677	Laboratoire	Cefpirome (Cefrom®) - Résumé des caractéristiques du produit Sanofi Aventis France 2008
3687	Laboratoire	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correard F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisolan et la kétamine. Pharmactuel 2019 ;52,4:206-213

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4445	Revue	Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D. Antibiotic compatibility and stability in a parenteral nutrition solution. Chemotherapy 1979 ; 25: 336-345.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis



Tobramycin sulfate









Stabilité des préparations

		2400 mg Nebcin®	NaCl 0.45% >> 30 ml	25°C	?	195		3431
		2400 mg Nebcin®	NaCl 0.45% >> 30 ml	4°C	?	195		3431








Stabilité en mélange

		NaCl 0.9% 2 ml	4°C	?	Salbutamol sulfate : Flacon injectable ® = ? 2,5 mg=0	7	2960
			25°C		Colistin mesilate sodium : Flacon injectable Colistin CF® 80mg/3mL	24	3440

		25°C		Colistin mesilate sodium : Flacon injectable Colistin CF® 80mg/3mL		3440
		25°C		Colistin mesilate sodium : Flacon injectable Colistin CF® 80mg/3mL		3440



Compatibilités


			
	Tobramycin sulfate Dornase alfa		3472




Bibliographie

	Type	Source
2960	Revue	Gooch MD. Stability of albuterol and tobramycin when mixed for aerosol administration. Respiratory Care 1991 ; 36: 1387-1390.
3431	Revue	Law S. Stability of preservative-free tobramycin in half-normal saline. Can J Hosp Pharm 2001 ; 54, 3: 214-215.
3440	Revue	Wollstadt A, Krämer I, Kamin W. Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin. Pharmazie 2013 ; 68: 744-748.
3472	Revue	Krämer I, Schwabe A, Kamin W. Physikalisch-chemische Kompatibilität von Mischinhalationslösungen und Suspensionen zur simultanen Feuchteinhalationstherapie bei Mukoviszidose Patienten. Krankenhauspharmazie 2007 ; 28, 5: 170-178.

Stabilis



Tobramycin sulfate



Stabilité en mélange

	POH benzoate de methyle 9,5 mg POH benzoate de propyle 3 mg Benzoate de sodium 10 mg Métabisulfite de sodium 7,5 mg NaHPO4 132,8 mg KCl 29,4 mg Na2HPO4 52, mg Eau purifiée >> 10 ml Ampho-Moronal® 5 ml	- + 2-8°C		Amphotericin B : Poudre @ = ? 500 mg Colistin sulfate : Poudre @ = ? 118 mg	 180	 3685



































































Bibliographie

	Type	Source
3685	Revue	Pfeifer C, Noll S, Gerecke H, Fassauer G, Jira T, Remane Y, Vogel J, Frontini R, Reinhardt R. A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements. EJHP 2017 ; 24:4 : 235-241



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	 Lumière
 Heure	 Chlorure de sodium 0,9%
 Non précisée	 Glucose 5%
 Ethylène vinyl acétate	 Seringue polypropylène
 Eau pour préparation injectable	 Elastomère en polyisoprène
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Aucun	 Dianéal® PD2 2.5% glucose (Baxter)
 Polyolefine	 Compatibilités
 Compatible	 Précipitation en 1 heure
 Incompatible	 Instabilité chimique
 Incompatibilité non précisée	 Précipitation immédiate
RL Ringer lactate	 Nutrition parentérale (mélange ternaire)
 Nutrition parentérale (mélange binaire)	 Précipitation en 7 heures
 Solvant spécifique	 Précipitation en 15 minutes
 Changement de couleur à 4 heures	 Instabilité de l'émulsion immédiate
 Précipitation en 4 heures	 Turbidité immédiate
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Intramusculaire
 Perfusion sous-cutanée	 Bibliographie
 Aérosol	 Stabilité des préparations
 Origine	 Excipient

	Flacon injectable		Polypropylène
	Solution buvable		Flacon plastique
	Dictionnaire		